PLIANT THERAPEUTICS, INC.
For the period ended Dec 31, 2025. Filed Mar 11, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 11, 2026
PLRX$0.80-1.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
(In thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities | ||
| Net loss | $(149,344) | $(210,304) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation expense | 1,696 | 2,125 |
| Stock-based compensation expense | 26,234 | 37,626 |
| Gain on sale of property plant and equipment | (44) | — |
| Non-cash operating lease expense | 3,277 | 3,451 |
| Amortization (accretion) on short-term investments | 3,956 | 2,510 |
| Loss on extinguishment of debt | 1,828 | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 2,541 | 4,717 |
| Other non-current assets | 43 | (43) |
| Accounts payable | (5,480) | 1,428 |
| Accrued liabilities | (12,167) | 3,807 |
| Operating lease liabilities | (876) | (820) |
| Net cash used in operating activities | (128,336) | (155,503) |
| Cash flows from investing activities | ||
| Purchase of short-term investments | (203,404) | (211,285) |
| Maturity of short-term investments | 337,913 | 355,473 |
| Purchase of property and equipment | (374) | (3,848) |
| Proceeds from sale of property, plant and equipment | 155 | — |
| Net cash provided by investing activities | 134,290 | 140,340 |
| Cash flows from financing activities | ||
| Proceeds from issuances of common stock under benefit plans | 570 | 3,207 |
| Payment of debt | (32,267) | — |
| Proceeds from term loan, net of issuance costs | — | 19,910 |
| Net cash (used in) provided by financing activities | (31,697) | 23,117 |
| Net (decrease) increase in cash and cash equivalents | (25,743) | 7,954 |
| Cash, cash equivalents and restricted cash at beginning of period | 72,670 | 64,716 |
| Cash, cash equivalents and restricted cash at end of period | $46,927 | $72,670 |
| Supplemental disclosures of cash flow information: | ||
| Cash paid for interest | $2,539 | $2,620 |
| Reconciliation of cash, cash equivalents, and restricted cash reported in the balance sheets | ||
| Cash and cash equivalents | $45,445 | $71,188 |
| Restricted cash | 1,482 | 1,482 |
| Total cash, cash equivalents, and restricted cash shown in the statements of cash flows | $46,927 | $72,670 |
| Supplemental disclosures of noncash investing and financing activities: | ||
| Purchase of property and equipment in accounts payable | $112 | $236 |
| Supplemental disclosures of cash flow information related to leases: | ||
| Cash paid for operating lease liabilities in operating cash flows | $5,562 | $4,698 |
| Right-of-use assets obtained in exchange for new operating lease liabilities | $— | $29,779 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.